Share Price, page-11178

Thank you - and yes it was due to the pricing construct for both, so thanks for explaining it.

(also acknowledge common is probably more appropriate way to label it than me saying 'mainstream')

but I wonder, if it makes more sense commercially, there's nothing stopping them from pivoting from rare to common down the line right - or would there be? Obviously not great for sufferes of the rare diseases

with regards to patents, do these apply to the drug itself or the drug being used for a particular disorder?

eg could a strategy be... to focus on the rare diseases for now (perhaps an easier pathway to commercialisation) and then prove out common disorders in the background, to launch when parents expire on Retts, PHS, PMD etc

Or is this still thinking and doesn't really work?